Jim Jenson, PhD

CEO, Morphoceuticals

Jim Jenson, PhD, is the Chief Executive Officer at Morphoceuticals. He has more than 35 years of experience in the biotech and pharmaceutical industries, as both an entrepreneur and executive leader. He most recently served as the Co-founder and CEO of CytoSite Biopharma Inc., which develops new technology to predict and monitor responses to immuno-oncology therapy. Jim was CEO and Co-founder of Dicerna Pharmaceuticals, Inc., a developer of RNAi based therapeutics, which Novo Nordisk acquired in 2021 for $3.3 billion. He was CEO and Co-founder of Zapaq Inc., which later merged with another company to form CoMentis. The company’s brain-accessible beta-secretase enzyme inhibitor for use in treating Alzheimer’s disease was licensed to Astellas in one of the largest deals of its kind. Jim also served in a variety of roles at Procept, Triton/Berlex (Director, Protein Chemistry, company acquired by Schering A.G.), and Hoffmann-LaRoche (Head of Molecular Immunology). He holds a PhD in Biology and Biochemistry from Cornell University and a BA in Biology from Macalester College.